Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Aug 16, 2022; 10(23): 8124-8132
Published online Aug 16, 2022. doi: 10.12998/wjcc.v10.i23.8124
Table 1 Demographic findings
Variables
Group A, n = 13
Group B, n = 24
P value
Sex (male/female)12/117/70.224
GA, wk29.5 ± 5.3 (23-39)31.7 ± 5.2 (23-39)0.216
Preterm/full term10/3 (76.9%)16/8 (66.7%)0.515
Birth weight, g 1479.2 ± 1071.2 (450-3670)1888.2 ± 986.5 (670-3450)0.189
Delivery (NSVD/CS)1/1210/140.057
Postnatal age at diagnosis, d 18.8 ± 29.9 (0-111)12.1 ± 18.5 (1~ 79)0.499
Apgar at 1 min4.0 ± 2.5 (0-8)4.3 ± 1.5 (0-8)0.936
Apgar at 5 min5.8 ± 2.0 (1-9)6.5 ± 1.5 (0-9)0.825
Table 2 Preceding clinical history before diagnosing a pneumoperitoneum
Variables
Group A, n = 13
Group B, n = 24
P value
Odds ratio, 95%CI
MV at birth (yes/no)12/117/70.2164.333
HFOV (yes/no)5/133/240.1004.375
PPHN (yes/no)7/62/220.00412.833
RDS (yes/no)11/215/90.2623.3
Pneumothorax (yes/no)6/71/230.00419.7
CPR (yes/no)3/102/220.3213.3
Vasopressor infusion (yes/no)11/212/120.0745.5
MV duration, d17.1 ± 30.2 (1-111)12.4 ± 21.7 (2-79)0.067-
Table 3 Laboratory findings at diagnosis and outcomes
Variables
Group A, n = 13
Group B, n = 24
P value
Blood sugar, mg% 152.1 ± 58.2 (69-235)148.3 ± 51.4 (85-294)0.790
CRP, IU/L1.28 ± 1.60 (0.01-4.88)2.24 ± 4.03 (0.03-17.94)0.649
WBC, 103/μL14641.5 ± 7008.6 (3810-25470)14568.8 ± 9349.4 (4410-37360)0.561
Segmented neutrophil, %57.5 ± 17.4 (20.3-87.0)62.1 ± 12.8 (34.1-81.4)0.479
PLT, 103/μL156.1 ± 115.9 (6.0-371.0)272.9 ± 143.8 (83.0-565.0)0.015
Thrombocytopenia8 / 135 / 240.013
pH7.26 ± 0.15 (6.95-7.43)7.27 ± 0.17 (6.92-7.48)0.696
PaO2, mmHg55.4 ± 19.2 (18.0-86.8)100.9 ± 58.3 (46.3-227.2)0.025
Overall mortality, %76.9 (10/13)16.6 (4/24)0.001
Table 4 Clinical characteristics and analysis of factor affecting mortality in group A, n = 13
Variables
No of cases (%)
P value
Odd ratio (95%CI)
Management
Non-operative5 (38.5)
Operation8 (61.5)
Mortality, overall10/13 (76.9)
Mortality in
Non-operative5/5 (100)
Operative5/8 (62.5)0.2310.625 (0.365-1.069)
Pneumothorax (+)6/6 (100)
Pneumothorax (-)4/7 (57.1)0.0671.750 (0.921-3.324)
PPHN (+)6/7 (85.7)
PPHN (-)4/6 (66.7)0.4163.0 (0.199-45.244)
RDS (+)9/11 (81.8)
RDS (-)1/2 (50.0)0.3264.5 (0.190-106.8)
HFOV (+)4/5 (80.0)
HFOV (-)6/8 (75.0)0.9121.333 (0.088-20.108)
Vasopressor (+)9/11 (81.8)
Vasopressor (-)1/2 (50.0)0.3264.5 (0.190-106.823)
CPR (+)3/3 (100)
CPR (-)7/10 (70.0)0.2791.429 (0.952-2.143)
Thrombocytopenia (+)7/8 (87.5)
Thrombocytopenia (-)3/5 (60.0)0.514.667 (0.197-73.384)
Full-term 1/3 (33.3)
Preterm 9/10 (90.0)0.04118.0 (0.758-427.291)
Table 5 Clinical characteristics of Group B, n = 24
Variable
Cases, n (%)
Associated gastrointestinal conditions
Gastric perforation7 (29.2)
NEC7 (29.2)
SIP2 (8.3)
HD4 (16.6)
Intestinal atresia1 (4.2)
EA /c TEF 2 (8.3)
Malrotation1 (4.2)
Mortality, overall4 (16.6)